A long-term study of gonadal function was conducted in 46 men and 28 women in prolonged remission of advanced Hodgkin's disease after cyclical combination chemotherapy with nitrogen mustard, vinblastine, prednisolone, and procarbazine. The mean follow-up was 6-9 years. Azoospermia or profound oligospermia occurred in 36 of the men, but late recovery was occasionally observed.
Introduction
The observation that gonadal damage may occur in patients treated with cytotoxic drugs was first made in 1956.1 "Conventional" cyclical combination chemotherapy for Hodgkin's disease has an immediate effect on spermatogenesis.' A similar though less dramatic effect on menstruation is seen, and the incidence of amenorrhoea correlates with the age of the patient at the time of treatment. 3 We report on the long-term consequences for gonadal function of this curative combination chemotherapy. We undertook this follow-up study to determine whether spermatogenesis recovered or menses returned several years after the completion of treatment.
Patients and methods
Patients-We studied 46 
Discussion
It is now possible to cure a high proportion of patients with advanced Hodgkin's disease4; partial or complete sterilisation, however, has to be accepted as a consequence of current chemotherapy. In this study 36 (88%) of the 41 men became azoospermic or severely oligospermic (less than one million sperm per ejaculate). A small proportion of men who had been under 30 years old at the start of treatment (20%/) showed partial recovery, although this was delayed by up to 10 years. None of the men developed impaired testosterone secretion or impotence.
Twenty-two (79%) of the 28 women became prematurely amenorrhoeic and deficient in gonadal hormones. Amenorrhoea was found to be permanent if menstruation failed to return three months after the completion of chemotherapy: this contrasts with the finding of Horning et al. 6 The hypogonadism appeared from the detailed hormonal assessment to result from primary gonadal failure. In men and women the incidence of hypogonadism increased with the age at the start of treatment.
In men storage of sperm might be thought to be a means of circumventing the sterilising effect of chemotherapy. This is precluded, however, by the surprisingly high incidence of oligospermia at presentation.7 In women oestrogen deficiency induced by treatment is associated with sterility,3 loss of libido,8 and premature osteoporosis. 9 Oestrogen replacement and counselling may prevent the latter sequelae of a premature menopause.
At present chemotherapy with MVPP, or minor variants, represents the only proved way of curing young adults with advanced Hodgkin's disease, which is otherwise invariably fatal. Thus this regimen will most probably remain central to the treatment of the disease in the near future, although preliminary reports suggest that an alternative combination is equally effective with no sterilising properties, and further studies are being carried out. '0 It has been suggested that continuous prophylactic administration of oestrogens before or during chemotherapy might protect the ovary. Chapman and Sutcliffe recently reported on a series of six patients from this hospital (not included above) who received oestrogen throughout chemotherapy and concluded, on the basis of retention of menses and results of ovarian biopsies in these patients, that protection had been afforded."' Caution must, however, be exercised in this interpretation, since all the patients were aged 30 or younger, two subsequently developed a premature menopause, and one had "menopausal" gonadotrophin concentrations. Additionally, these findings conflict with those in another, larger series.'2 In spite of these reservations the hypothesis that "switching off" the gonad during treatment might protect it from chemotherapy is attractive and presents the only immediately possible prospect of avoiding the chemical sterilisation that is currently inevitable for most cured patients.
